Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array)
MMPL; PLP/DM20; PMD; SPG2; Pelizaeus-Merzbacher Disease; Spastic Paraplegia 2,Uncomplicated; Myelin proteolipid protein; Lipophilin
- Product No.CMA417Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typetissue homogenates, cell lysates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length4h
- Detection Range0.0098-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.0033ng/mL.
- DownloadInstruction Manual
- UOM 48T96T
- FOB
US$ 669
US$ 955
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 91-105 | 98 |
| EDTA plasma(n=5) | 95-105 | 101 |
| heparin plasma(n=5) | 88-98 | 93 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Proteolipid Protein 1, Myelin (PLP1) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 95-102% | 98-105% | 86-97% | 79-95% |
| EDTA plasma(n=5) | 90-97% | 83-104% | 97-104% | 93-101% |
| heparin plasma(n=5) | 95-104% | 78-95% | 79-98% | 78-96% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Brain Pathology | Pathophysiology of Hypoperfusion of the Precuneus in Early Alzheimer's Disease PubMed: 26452729 |
| Alzheimers Research & Therapy | Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be … Pubmed: 31511061 |
| Brain Pathol | Mediators of cerebral hypoperfusion and blood©\brain barrier leakiness in alzheimer's disease, vascular dementia and mixed dementia 33410232 |